Cardiac allograft vasculopathy: current knowledge and future direction
- 1 March 2011
- journal article
- review article
- Published by Wiley in Clinical Transplantation
- Vol. 25 (2) , 175-184
Abstract
Colvin‐Adams M, Agnihotri A. Cardiac allograft vasculopathy: current knowledge and future direction. Clin Transplant 2011: 25: 175–184. © 2011 John Wiley & Sons A/S.Abstract: Cardiac allograft vasculopathy (CAV) is a unique form of coronary artery disease affecting heart transplant recipients. Although prognosis of heart transplant recipients has improved over time, CAV remains a significant cause of mortality beyond the first year of cardiac transplantation. Many traditional and non‐traditional risk factors for the development of CAV have been described. Traditional risk factors include dyslipidemia, diabetes and hypertension. Non‐traditional risk factors include cytomegalovirus infection, HLA mismatch, antibody‐mediated rejection, and mode of donor brain death. There is a complex interplay between immunological and non‐immunological factors ultimately leading to endothelial injury and exaggerated repair response. Pathologically, CAV manifests as fibroelastic proliferation of intima and luminal stenosis. Early diagnosis is paramount as heart transplant recipients are frequently asymptomatic owing to cardiac denervation related to the transplant surgery. Intravascular ultrasound (IVUS) offers many advantages over conventional angiography and is an excellent predictor of prognosis in heart transplant recipients. Many non‐invasive diagnostic tests including dobutamine stress echocardiography, CT angiography, and MRI are available; though, none has replaced angiography. This review discusses the risk factors, pathogenesis, and diagnosis of CAV and highlights some current concepts and recent developments in this field.Keywords
This publication has 111 references indexed in Scilit:
- Systemic Inflammation and Metabolic Syndrome in Cardiac Allograft VasculopathyThe Journal of Heart and Lung Transplantation, 2007
- Is Brain Natriuretic Peptide Clinically Useful After Cardiac Transplantation?The Journal of Heart and Lung Transplantation, 2006
- Gene Expression Profiles and B-Type Natriuretic Peptide Elevation in Heart TransplantationCirculation, 2006
- Epicardial Stenosis Severity Does Not Affect Minimal Microcirculatory ResistanceCirculation, 2004
- Microvascular Resistance Is Not Influenced by Epicardial Coronary Artery Stenosis SeverityCirculation, 2004
- Prediction of mortality in heart transplant recipients by stress technetium-99m tetrofosmin myocardial perfusion imagingThe American Journal of Cardiology, 2002
- Risk for posttransplant diabetes mellitus with current immunosuppressive medicationsAmerican Journal of Kidney Diseases, 1999
- Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factorsThe American Journal of Cardiology, 1994
- Frequency of angiographic detection and quantitative assessment of coronary arterial disease one and three years after cardiac transplantationThe American Journal of Cardiology, 1989
- Cardiac Transplantation in ManCirculation, 1970